0302 BrainStorm
BioCentury & BioRender

Product Development

FDA seeks to dampen expectations on BrainStorm ALS therapy amid patient push for access

Mar 3, 2021 | 2:23 AM GMT

In the face of a social media campaign by patients advocating for the access to BrainStorm’s ALS therapy NurOwn, FDA took the highly unusual step of commenting on the results of a Phase III trial before

Read the full 610 word article

How to gain access

Continue reading with a
two-week free trial.